Initial experience of the adjuvant treatments to the local tumor for metastatic prostate cancer: Assessment of novel treatment algorithms, a multicenter, phase II randomized controlled trial (IP2-ATLANTA).

Published on May 25, 2020in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2020.38.15_SUPPL.TPS5600
Martin J. Connor10
Estimated H-index: 10
(Imperial College London),
Taimur T. Shah14
Estimated H-index: 14
(Imperial College London)
+ 17 AuthorsHashim U. Ahmed62
Estimated H-index: 62
(Imperial College London)
Source
Abstract
TPS5600Background: Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit beyond standard systemic therapy in patients with de novo synchro...
📖 Papers frequently viewed together
15 Citations
References0
Newest
Cited By1
Newest
#1Martin J. ConnorH-Index: 10
#2Taimur T. Shah (Imperial College London)H-Index: 14
Last. Hashim U. AhmedH-Index: 62
view all 36 authors...
Introduction Survival in men diagnosed with de novo synchronous metastatic prostate cancer has increased following the use of upfront systemic treatment, using chemotherapy and other novel androgen receptor targeted agents, in addition to standard androgen deprivation therapy (ADT). Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit. In this setting, IP2-ATLANTA will explore progression-free survival (PFS) outcomes with the addition o...
1 CitationsSource